AZNAstraZenecaFinished
A Phase 3b, Open-label, Multi-center Study on Durvalumab in Combination With Gemcitabine-based Chemotherapy as 1L Treatment for the Chinese Patients With Unresectable Biliary Tract Cancers (BTC)
Biliary Tract Cancers
10Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +10
Main results were due Feb 2025, none posted yet
Counts until it's fixed
Worry score10
Score over time
- Stage
- Phase 3
- Patients
- 116 (final count)
- Started
- Jul 21, 2023
- Main results expected
- Feb 7, 2025
- Fully finished
- Feb 7, 2025
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
The incidence of Possible related adverse events(PRAE) Grade 3 or 4
Measured over: Within 6 months after the initiation of study intervention.
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- results_overdue: base 10, now 10, since 2025-02-07, no fading
Raw record changes
- none yet
Trial ID NCT05924880 · record last updated 2025-04-22 · checked 2026-11-09 15:47 UTC